Filing Flows › Bioventus (BVS) › Q1 2026
Bioventus (BVS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Bioventus (BVS) reported revenue of $132M for the first quarter 2026 (Q1 2026), +7% from a year earlier and -16% from the quarter before. Operating margin was 6.4%, net earnings $3.1M (2.4% of revenue).
Bioventus, Q1 2026: revenue $132M (+7% year over year), operating margin 6.4%, net earnings $3.1M, operating cash flow $8.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $132M | -16% | +7% |
| Gross profit | $90.8M | -17% | +9% |
| Operating profit | $8.4M | -57% | +73% |
| Net earnings | $3.1M | -79% | — |
| Operating cash flow | $8.9M | -76% | — |
| Free cash flow | $8.4M | -78% | — |
What changed
Revenue was $132.1M in Q1 2026, up 7% year over year and down 16% from the previous quarter.
Gross margin was 68.7%, up 1.7 points from Q1 2025. Operating profit was $8.4M, a 6.4% margin (up 2.4 points year over year). Of the extra revenue versus Q1 2025, 43% reached operating profit, above the 4% margin then. Operating expenses grew 5% against revenue growth of 7%. Net earnings were $3.1M. The effective tax rate was 12.6%.
Operating cash flow was $8.9M, 226% of net income including minority interests. Non-cash charges added back $11.2M of depreciation and amortization and $3.3M of share-based compensation. Working capital and other items used $9.5M. Capital expenditures of $574K left free cash flow of $8.4M.
Questions
What was Bioventus' revenue in the first quarter 2026?
Bioventus (BVS) reported revenue of $132M for the first quarter 2026 (Q1 2026), +7% from a year earlier and -16% from the quarter before.
Was Bioventus profitable in the first quarter 2026?
Operating profit was $8.4M (6.4% of revenue) and net earnings $3.1M.
Source: Bioventus 10-Q on SEC EDGAR.